Do immune check inhibitors have a role in the treatment of higher-risk MDS? [MDS Professional Report‪]‬ MDS Professional Report

Chien Aza – Pembro - BJH
The combination of azacitidine and pembrolizumab may be a potential effective regimen for patients with higher-risk MDS and may lead to the introduction of an important class of medications into MDS practice

Nazha, Prog model – JCO
A personalized prediction model, based on clinical and genomic data, outperformed established prognostic models in MDS. The use of digital tools allow us to manage big data taken from large numbers of patients and include them in the newly developed diagnostic and prognostic models.


Keundgen , t-MDS- Leukemia
Therapy-related MDS should be classified as a separate entity distinct from other WHO-classified t-myeloid neoplasms, which would enhance treatment decisions and facilitate the inclusion of t-MDS patients into clinical studies.


Strapatsas, PLT, Ann Hem

The authors re-confirm the importance of PLT count as a prognostic factor in MDS, both at presentation and during the disease course. Bleeding is a leading (3rd ) cause of death in these patients.